• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国初级保健中症状性卵巢癌的早期诊断:机遇与挑战。

Early diagnosis of symptomatic ovarian cancer in primary care in the UK: opportunities and challenges.

机构信息

Faculty of Life Sciences and Medicine, King's College London, Guy's Campus, LondonSE1 1UL, UK.

Cambridge Academy of Therapeutic Sciences, University of Cambridge, 17 Mill Lane, CambridgeCB2 1RX, UK.

出版信息

Prim Health Care Res Dev. 2022 Sep 2;23:e52. doi: 10.1017/S146342362200041X.

DOI:10.1017/S146342362200041X
PMID:36052862
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9472236/
Abstract

BACKGROUND

Ovarian cancer is the sixth most common cause of cancer-related death in the UK amongst women. Ovarian cancer presents particular challenges for general practitioners (GPs) to diagnose due to its rarity and presentation with non-specific symptoms.

METHODS

A narrative overview of the literature was conducted by searching PubMed and Researchgate for relevant articles, using keywords such as "ovarian cancer," "primary care" and "diagnosis."

RESULTS AND DISCUSSION

Studies have shown that in the UK, GPs have a lower readiness to refer and investigate potential cancer symptoms compared with their international counterparts; and this has been correlated with reduced survival. Early diagnosis can be facilitated through a people-focussed and system-based approach which involves both educating GPs and using risk algorithms, rapid diagnostic centres/multi-disciplinary centres and being data-driven through the identification of best practice from national audits. Further research is required into the best evidence-based early investigations for ovarian cancer and more effective biomarkers.

摘要

背景

在英国,卵巢癌是女性癌症相关死亡的第六大常见原因。由于其罕见性和非特异性症状表现,全科医生(GP)在诊断卵巢癌方面面临特殊挑战。

方法

通过在 PubMed 和 Researchgate 上搜索相关文章,使用“卵巢癌”、“初级保健”和“诊断”等关键词,对文献进行了叙述性综述。

结果与讨论

研究表明,在英国,与国际同行相比,全科医生在转诊和调查潜在癌症症状方面的准备程度较低;这与生存率降低有关。通过以人为本和以系统为基础的方法可以促进早期诊断,该方法既包括对全科医生进行教育,又包括使用风险算法、快速诊断中心/多学科中心,并通过从国家审计中确定最佳实践来实现数据驱动。需要进一步研究卵巢癌的最佳循证早期检查方法和更有效的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da6/9472236/e76b174e8482/S146342362200041X_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da6/9472236/2d33abdb333c/S146342362200041X_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da6/9472236/754781d1b4a9/S146342362200041X_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da6/9472236/e76b174e8482/S146342362200041X_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da6/9472236/2d33abdb333c/S146342362200041X_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da6/9472236/754781d1b4a9/S146342362200041X_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da6/9472236/e76b174e8482/S146342362200041X_fig3.jpg

相似文献

1
Early diagnosis of symptomatic ovarian cancer in primary care in the UK: opportunities and challenges.英国初级保健中症状性卵巢癌的早期诊断:机遇与挑战。
Prim Health Care Res Dev. 2022 Sep 2;23:e52. doi: 10.1017/S146342362200041X.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
3
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.术中冰冻切片分析用于诊断可疑盆腔肿块中的早期卵巢癌。
Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2.
7
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
8
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
9
Clinical judgement by primary care physicians for the diagnosis of all-cause dementia or cognitive impairment in symptomatic people.初级保健医生对有症状人群进行全因痴呆或认知障碍诊断的临床判断。
Cochrane Database Syst Rev. 2022 Jun 16;6(6):CD012558. doi: 10.1002/14651858.CD012558.pub2.
10
How to Implement Digital Clinical Consultations in UK Maternity Care: the ARM@DA Realist Review.如何在英国产科护理中实施数字临床会诊:ARM@DA实证主义综述
Health Soc Care Deliv Res. 2025 May 21:1-77. doi: 10.3310/WQFV7425.

引用本文的文献

1
Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment.未来的诊疗策略:新兴的卵巢癌生物标志物以弥合诊断与治疗之间的差距。
Front Drug Deliv. 2024 Feb 1;4:1339936. doi: 10.3389/fddev.2024.1339936. eCollection 2024.
2
Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer.嵌合抗原受体(CAR)-NK92细胞在体外以及卵巢癌小鼠异种移植模型中对胶质母细胞瘤、乳腺癌和胰腺癌有效。
Cancer Cell Int. 2025 Jul 11;25(1):260. doi: 10.1186/s12935-025-03865-0.
3
Inflammatory Indices and CA 125: A New Approach to Distinguish Ovarian Carcinoma and Borderline Tumors in Suspicious Ovarian Neoplasms from a Retrospective Observational Multicentric Study.

本文引用的文献

1
Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.综合上皮性输卵管-卵巢癌风险预测模型,纳入遗传和流行病学风险因素。
J Med Genet. 2022 Jul;59(7):632-643. doi: 10.1136/jmedgenet-2021-107904. Epub 2021 Nov 29.
2
Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK.由 COVID-19 大流行期间诊断延误导致的可避免癌症死亡的经济影响:英国英格兰基于人群的全国建模研究。
Eur J Cancer. 2021 Jul;152:233-242. doi: 10.1016/j.ejca.2021.04.019. Epub 2021 May 5.
3
炎症指标与CA 125:一项回顾性观察多中心研究中鉴别可疑卵巢肿瘤中卵巢癌和交界性肿瘤的新方法
Medicina (Kaunas). 2025 Apr 22;61(5):777. doi: 10.3390/medicina61050777.
4
Emerging nanotechnologies and their role in early ovarian cancer detection, diagnosis and interventions.新兴纳米技术及其在早期卵巢癌检测、诊断和干预中的作用。
J Ovarian Res. 2025 May 7;18(1):96. doi: 10.1186/s13048-025-01678-3.
5
The Integrated Bioinformatic Approach Reveals the Prognostic Significance of LRP1 Expression in Ovarian Cancer.综合生物信息学方法揭示 LRP1 表达在卵巢癌中的预后意义。
Int J Mol Sci. 2024 Jul 22;25(14):7996. doi: 10.3390/ijms25147996.
6
Comparative Review on Cancer Pathology from Aberrant Histone Chaperone Activity.从异常组蛋白伴侣活性看癌症病理学的比较研究
Int J Mol Sci. 2024 Jun 10;25(12):6403. doi: 10.3390/ijms25126403.
7
Construction of an exosome-associated miRNA-mRNA regulatory network and validation of and miR-17-5p as potential biomarkers associated with ovarian cancer.构建外泌体相关的miRNA-mRNA调控网络并验证miR-17-5p作为与卵巢癌相关的潜在生物标志物。
Transl Cancer Res. 2024 Feb 29;13(2):1052-1067. doi: 10.21037/tcr-23-940. Epub 2024 Feb 28.
8
Using online search activity for earlier detection of gynaecological malignancy.利用在线搜索活动进行妇科恶性肿瘤的早期检测。
BMC Public Health. 2024 Mar 11;24(1):608. doi: 10.1186/s12889-024-17673-0.
9
Deep learning in ovarian cancer diagnosis: a comprehensive review of various imaging modalities.深度学习在卵巢癌诊断中的应用:对各种成像方式的全面综述
Pol J Radiol. 2024 Jan 22;89:e30-e48. doi: 10.5114/pjr.2024.134817. eCollection 2024.
10
Clinicopathologic Impact of NANOG, ZEB1, and EpCAM Biomarkers on Prognosis of Serous Ovarian Carcinoma.NANOG、ZEB1 和 EpCAM 生物标志物对浆液性卵巢癌预后的临床病理影响。
Asian Pac J Cancer Prev. 2023 Sep 1;24(9):3247-3259. doi: 10.31557/APJCP.2023.24.9.3247.
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
英国卵巢癌筛查协作试验(UKCTOCS)长期随访后的卵巢癌人群筛查和死亡率:一项随机对照试验。
Lancet. 2021 Jun 5;397(10290):2182-2193. doi: 10.1016/S0140-6736(21)00731-5. Epub 2021 May 12.
4
The effectiveness of the Guy's Rapid Diagnostic Clinic (RDC) in detecting cancer and serious conditions in vague symptom patients.盖伊快速诊断诊所(RDC)在诊断模糊症状患者的癌症和严重疾病方面的效果。
Br J Cancer. 2021 Mar;124(6):1079-1087. doi: 10.1038/s41416-020-01207-7. Epub 2021 Jan 5.
5
CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants.CanRisk 工具——用于预测乳腺癌和卵巢癌风险以及携带遗传致病性变异可能性的网络界面。
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):469-473. doi: 10.1158/1055-9965.EPI-20-1319. Epub 2020 Dec 17.
6
Identifying Ovarian Cancer in Symptomatic Women: A Systematic Review of Clinical Tools.在有症状女性中识别卵巢癌:临床工具的系统评价
Cancers (Basel). 2020 Dec 8;12(12):3686. doi: 10.3390/cancers12123686.
7
The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.CA125 用于初级保健中卵巢癌和非卵巢癌检测的诊断性能:一项基于人群的队列研究。
PLoS Med. 2020 Oct 28;17(10):e1003295. doi: 10.1371/journal.pmed.1003295. eCollection 2020 Oct.
8
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.《COVID-19 大流行对英国英格兰因诊断延误导致的癌症死亡人数的影响:一项全国性基于人群的建模研究》。
Lancet Oncol. 2020 Aug;21(8):1023-1034. doi: 10.1016/S1470-2045(20)30388-0. Epub 2020 Jul 20.
9
First results from five multidisciplinary diagnostic centre (MDC) projects for non-specific but concerning symptoms, possibly indicative of cancer.五项多学科诊断中心(MDC)项目针对非特异性但令人担忧的症状的初步结果,这些症状可能提示癌症。
Br J Cancer. 2020 Sep;123(5):722-729. doi: 10.1038/s41416-020-0947-y. Epub 2020 Jul 6.
10
Association between use of urgent suspected cancer referral and mortality and stage at diagnosis: a 5-year national cohort study.使用紧急疑似癌症转诊与死亡率和诊断时分期的关系:一项为期 5 年的全国队列研究。
Br J Gen Pract. 2020 May 28;70(695):e389-e398. doi: 10.3399/bjgp20X709433. Print 2020 Jun.